FGF23‐mediated hypophosphatemia following saccharated ferric oxide administration during nutritional rehabilitation in anorexia nervosa: A case report

Background Hypophosphatemia is a clinically important complication of nutritional rehabilitation in patients with anorexia nervosa (AN). Refeeding‐related hypophosphatemia is often suspected initially. However, persistent hypophosphatemia despite phosphate supplementation or an atypical biochemical pattern should prompt evaluation for alternative causes. Intravenous iron is a recognized cause of fibroblast growth factor 23 (FGF23)‐mediated hypophosphatemia. However, longitudinal documentation of intact FGF23 and renal phosphate handling before and after intravenous iron exposure during nutritional rehabilitation for severe AN remains limited. Case Presentation A 17‐year‐old female with restricting‐type AN and severe malnutrition (body mass index, 13.2 kg/m 2 ) was admitted for nutritional rehabilitation. She had severe iron‐deficiency anemia and received intravenous saccharated ferric oxide. Hypophosphatemia developed despite prophylactic phosphate supplementation and persisted despite escalation of oral supplementation and the addition of intravenous phosphate replacement. Refeeding‐related hypophosphatemia was initially suspected. However, the percentage tubular reabsorption of phosphate (%TRP) and tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR) were markedly reduced during hypophosphatemia, indicating inappropriate renal phosphate wasting. Serial measurements demonstrated a transition from a normal pre‐exposure intact FGF23 concentration (36.4 pg/mL) to marked FGF23 excess (782–838 pg/mL), followed by a progressive decline after iron withdrawal. Serum phosphate gradually recovered. No symptoms or organ dysfunction attributable to hypophosphatemia occurred. Conclusion Hypophosphatemia during nutritional rehabilitation in AN should not automatically be attributed to refeeding‐related mechanisms. Persistent hypophosphatemia despite supplementation, particularly when accompanied by renal phosphate wasting, should prompt reassessment of the underlying mechanism and evaluation for FGF23‐mediated hypophosphatemia in patients exposed to intravenous iron.

Authors

Institutions

Publication Details

Journal
Psychiatry and Clinical Neurosciences Reports
Published
2026-11-18
DOI
https://doi.org/10.1002/pcn5.70448
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FGF23‐mediated hypophosphatemia following saccharated ferric oxide administration during nutritional rehabilitation in anorexia nervosa: A case report

Yuki Nagata, Koki Inoue, Tomoko Harada, Takumi Matsuzuka et al.
Psychiatry and Clinical Neurosciences Reports
Parathyroid Disorders and Treatments
article

FGF23‐mediated hypophosphatemia following saccharated ferric oxide administration during nutritional rehabilitation in anorexia nervosa: A case report

Yuki Nagata, Koki Inoue, Tomoko Harada, Takumi Matsuzuka, Masafumi Kurajoh, Yukia Nishiue, Kazuya Nishimoto
article en

Abstract

Background Hypophosphatemia is a clinically important complication of nutritional rehabilitation in patients with anorexia nervosa (AN). Refeeding‐related hypophosphatemia is often suspected initially. However, persistent hypophosphatemia despite phosphate supplementation or an atypical biochemical pattern should prompt evaluation for alternative causes. Intravenous iron is a recognized cause of fibroblast growth factor 23 (FGF23)‐mediated hypophosphatemia. However, longitudinal documentation of intact FGF23 and renal phosphate handling before and after intravenous iron exposure during nutritional rehabilitation for severe AN remains limited. Case Presentation A 17‐year‐old female with restricting‐type AN and severe malnutrition (body mass index, 13.2 kg/m 2 ) was admitted for nutritional rehabilitation. She had severe iron‐deficiency anemia and received intravenous saccharated ferric oxide. Hypophosphatemia developed despite prophylactic phosphate supplementation and persisted despite escalation of oral supplementation and the addition of intravenous phosphate replacement. Refeeding‐related hypophosphatemia was initially suspected. However, the percentage tubular reabsorption of phosphate (%TRP) and tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR) were markedly reduced during hypophosphatemia, indicating inappropriate renal phosphate wasting. Serial measurements demonstrated a transition from a normal pre‐exposure intact FGF23 concentration (36.4 pg/mL) to marked FGF23 excess (782–838 pg/mL), followed by a progressive decline after iron withdrawal. Serum phosphate gradually recovered. No symptoms or organ dysfunction attributable to hypophosphatemia occurred. Conclusion Hypophosphatemia during nutritional rehabilitation in AN should not automatically be attributed to refeeding‐related mechanisms. Persistent hypophosphatemia despite supplementation, particularly when accompanied by renal phosphate wasting, should prompt reassessment of the underlying mechanism and evaluation for FGF23‐mediated hypophosphatemia in patients exposed to intravenous iron.

Psychiatry and Clinical Neurosciences ReportsVol. 5(4)
Toyonaka Municipal Hospital (JP), Toyokawa City Hospital (JP), Osaka Metropolitan University (JP), Tokyo Metropolitan University (JP)
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon